Martin TJ - Search Results

1

Lack of effect of gliclazide on early diabetic nephropathy and retinopathy: a two-year controlled study.

Jerums G, Murray RM, Seeman E, Cooper ME, Edgley S, Marwick K, Larkins RG, Martin TJ. Jerums G, et al. Among authors: martin tj. Diabetes Res Clin Pract. 1987 Mar-Apr;3(2):71-80. doi: 10.1016/s0168-8227(87)80010-4. Diabetes Res Clin Pract. 1987. PMID: 3552537 Clinical Trial.

2

Lack of effect of gliclazide on platelet aggregation in insulin-treated and non-insulin-treated diabetes: a two-year controlled study.

Larkins RG, Jerums G, Taft JL, Godfrey H, Smith IL, Martin TJ. Larkins RG, et al. Among authors: martin tj. Diabetes Res Clin Pract. 1988 Jan 7;4(2):81-7. doi: 10.1016/s0168-8227(88)80001-9. Diabetes Res Clin Pract. 1988. PMID: 3125029 Clinical Trial.

3

Bone remodelling: its local regulation and the emergence of bone fragility.

Martin TJ, Seeman E. Martin TJ, et al. Best Pract Res Clin Endocrinol Metab. 2008 Oct;22(5):701-22. doi: 10.1016/j.beem.2008.07.006. Best Pract Res Clin Endocrinol Metab. 2008. PMID: 19028353 Review.

4

A comparison of single and multiple intravenous infusions of 3-amino-1-hydroxypropylidene-1, 1-bisphosphonate (APD) in the treatment of hypercalcemia of malignancy.

Yates AJ, Murray RM, Jerums GJ, Martin TJ. Yates AJ, et al. Among authors: martin tj. Aust N Z J Med. 1987 Aug;17(4):387-91. doi: 10.1111/j.1445-5994.1987.tb00070.x. Aust N Z J Med. 1987. PMID: 3435316

5

Calcitonin effects on growth and on selective activation of type II isoenzyme of cyclic adenosine 3':5'-monophosphate-dependent protein kinase in T 47D human breast cancer cells.

Ng KW, Livesey SA, Larkins RG, Martin TJ. Ng KW, et al. Among authors: martin tj. Cancer Res. 1983 Feb;43(2):794-800. Cancer Res. 1983. PMID: 6184157

6

Non-invasive techniques for the measurement of bone mineral.

Seeman E, Martin TJ. Seeman E, et al. Among authors: martin tj. Baillieres Clin Endocrinol Metab. 1989 May;3(1):1-33. doi: 10.1016/s0950-351x(89)80021-7. Baillieres Clin Endocrinol Metab. 1989. PMID: 2679520 Review.

7

New mechanisms and targets in the treatment of bone fragility.

Martin TJ, Seeman E. Martin TJ, et al. Clin Sci (Lond). 2007 Jan;112(2):77-91. doi: 10.1042/CS20060046. Clin Sci (Lond). 2007. PMID: 17155930 Review.

8

Circulating PTH and PTHrP levels before and after treatment of tumor induced hypercalcemia with Pamidronate Disodium (APD).

Grill V, Murray RM, Ho PW, Santamaria JD, Pitt P, Potts C, Jerums G, Martin TJ. Grill V, et al. Among authors: martin tj. J Clin Endocrinol Metab. 1992 Jun;74(6):1468-70. doi: 10.1210/jcem.74.6.1592895. J Clin Endocrinol Metab. 1992. PMID: 1592895

9

Antiresorptive and anabolic agents in the prevention and reversal of bone fragility.

Seeman E, Martin TJ. Seeman E, et al. Among authors: martin tj. Nat Rev Rheumatol. 2019 Apr;15(4):225-236. doi: 10.1038/s41584-019-0172-3. Nat Rev Rheumatol. 2019. PMID: 30755735 Review.

10

The boundaryless hospital--a commentary.

Larkins RG, Martin TJ, Johnston CI. Larkins RG, et al. Among authors: martin tj. Aust N Z J Med. 1995 Apr;25(2):169-70. doi: 10.1111/j.1445-5994.1995.tb02832.x. Aust N Z J Med. 1995. PMID: 7605302 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

850 results

Search Page